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Chapter 1: Introduction 
The pregnane X receptor (PXR, also known as SXR or NR1I2) was identified by three 
different research groups in 1998 as a member of the nuclear receptor superfamily of ligand 
activated transcription factors (Figure 1). PXR is mainly expressed in the liver and intestine ‒ the 
major organs where detoxification occurs. PXR plays an important role in the activation of many 
drug metabolizing enzymes and membrane-bound drug transporters. PXR has attracted a 
particular attention because of its enlarged, flexible, hydrophobic ligand binding domain (LBD) 
that allows PXR to be activated by a large variety of substances. Moreover, recent studies have 
revealed the involvement of PXR in many physiological functions other than drug metabolism, 
such as inflammation, vitamin D metabolism, bile synthesis, energy and lipid homeostasis, and 
cancer. 
Vitamin K (VK) is a well-known nutrient that acts as a co-factor of γ-glutamyl 
carboxylase and plays an important role in blood coagulation and bone formation. Inadequate 
intake of VK may be associated with osteoporosis, oseteoarthritis, Alzheimer’s disease, and 
coronary artery disease. Menaquinone-4 (MK-4) is a vitamin K2 analog, which has been used as 
a therapeutic agent in osteoporosis in many East and South East Asia countries. 
In 2003, it was demonstrated that MK-4 directly binds to and transcriptionally activates 
PXR as well as promotes the association between PXR and coactivators. Activated PXR, in turn, 
plays an important role in bone homeostasis by modulating gene expression. However, the 
research related to the PXR-mediated effects of MK-4 has concentrated mostly on bone 
physiology and cell-based experiments. Therefore, potential effects of MK-4 mediated activation 
of PXR should be investigated in other organs. This may shed light on many mechanisms related 
to diseases in which VK can be used as a preventive or therapeutic agent. 
Species-specific ligand preference by PXR constitutes a significant challenge for the 
studies of PXR function. The species-specific preferences shows that evaluation of toxicity and 
functionality of PXR ligands in rodents has an inherent limitation as it may not be readily 
translated into human physiology. To overcome this issue, several groups of researchers have 
developed a mouse model with humanized PXR (hPXR) by using different strategies.  
The purpose of the present study was to investigate the novel function of MK-4 in the 
humanized mouse line (hPXR) in which the LBD region of the human PXR gene was 
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homologously knocked-in to the mouse Pxr gene, replacing the sequence that encoded 
endogenous LBD. 
 
 
Chapter 2: Validation of the diet and animal 
In this study, WT mice and hPXR mice in which the LBD of the human PXR is knocked-
in to the mice replacing the endogenous LBD (Figure 2) were used. Therefore, it was necessary 
to establish a condition where environment has no effect on PXR target gene expression in both 
types of mice. For this purpose, the effect of two common commercially available non-purified 
diets [F2 (Funabashi Farm) and CRF-1 (Oriental Yeast)] were investigated. Moreover, the 
responses of PXR in WT mice and human PXR in hPXR mice to the specific ligands were 
investigated by the treatment of pregnane 16α-carbonitrile (PCN) and rifampicin (Rif). PCN is a 
much stronger activator of rat or mouse PXR than of human PXR, on the other hand, Rif is a 
strong activator of human PXR but a very weak activator of mouse or rat PXR. PXR plays an 
important role in the gene expression of many drug metabolizing enzymes and membrane-bound 
drug transporters. Cyp3a11, Ces2a and Mdr1 are very common target genes of PXR involved in 
drug metabolism. Therefore, first the effects of PCN, Rif and diet on the expression of these 
genes were investigated. 
It was found that the basal mRNA levels of Cyp3a11, Ces2a and Mdr1 were significantly 
high in liver of hPXR mice compared to WT mice when the mice were maintained on F2 diet 
(Figure 3). In contrast, there is no significant difference in the basal mRNA levels of Cyp3a11, 
Ces2a and Mdr1 in the liver (Figure 4) of WT and hPXR mice. Therefore, mice were maintained 
on CRF-1 diet throughout the study. 
Moreover, in accordance with other studies, it was found that mRNA levels of all of the 
tested genes were significantly increased by the treatment of PCN in liver of WT mice. In 
contrast, no significant change was observed in case of hPXR mice. Similarly, no significant 
change in the mRNA levels of Cyp3a11, Ces2a or Mdr1 was observed in liver of WT mice when 
treated by Rif. In contrast, the mRNA levels of all the genes were significantly increased by the 
treatment of Rif in hPXR mice. 
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Chapter 3: Effects of single dose of MK-4 treatment on the expression of genes 
involved in drug metabolism, bile synthesis and energy homeostasis in mice. 
MK-4 acts as a ligand of PXR. However, species specific effect of PXR activation by 
MK-4 is not yet revealed. Here, the effect of single administration of MK-4 on the gene 
expression in WT and hPXR mice was investigated. 
First, it was important to find out proper time for the investigation of the effects of MK-4 
on the expression of genes. Because there is a very limited data regarding the bioavailability of 
MK-4 in animal, a time-course experiment was conducted in WT mice. The MK-4 content in the 
liver was measured by high performance liquid chromatography (HPLC) at different time 
interval after treatment in mice. It was found that MK-4 was rapidly absorbed by the liver. 
Moreover, within 9 h of the treatment, MK-4 content was drastically reduced in the liver (Figure 
5). Therefore, 6 h duration of treatment was used in the following experiment. 
It was hypothesized that MK-4 may affect the expression of genes encoding the proteins 
involved in drug metabolism. Therefore, first the effects of single administration of 100 mg/kg 
BW MK-4 was investigated in the alteration of the expression of common PXR target genes 
involved in drug metabolism by quantitative RT PCR (qRT PCR). Moreover, this effect was 
compared with the effects of single administration of 50 mg/kg BW rifampicin treatment. To 
establish whether genes other than those involved in drug metabolism are affected by the 
treatment with MK-4, the DNA microarray assay was performed. Later, the effects of single 
administration of lower doses of MK-4 (10 or 50 mg/kg BW) on the mRNA levels of bile acid 
synthesis and energy homeostasis genes were investigated  
MK-4 content in the liver by fluorescence HPLC was determined. MK-4 content was 
elevated in a dose-dependent manner, but no significant difference was observed between MK-4 
levels in hPXR and WT mice except for when the highest dose of MK-4 was used (Figure 6). 
No significant change in the mRNA levels of the analyzed genes in the liver of WT 
(Figure 7A) or hPXR mice (Figure 7B) was found after single dose of 100 mg/kg BW MK-4 
treatment. 
Venn diagram shows the differentially expressed genes between 
rifampicin/menaquinone-4 treated and control mice in DNA microarray analysis (Figure 8). 
Genes that were (A) up-regulated (more than twice), (B) down-regulated (to below 0.5-fold), or 
(C) overall differentially expressed after the treatment with Rif or MK-4 in comparison with the 
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levels in control (Cont) hPXR mice are shown. Genes that were (D) up-regulated (more than 
twice), (E) down-regulated (to below 0.5-fold), or (F) overall differentially expressed in 
comparison with the levels in control WT and hPXR mice are also shown in Figure 8. 
Selected genes, whose expression was up-regulated (to more than twice) or down-
regulated (to below 0.5-fold) in MK-4 and Rif treated groups in comparison with that in control, 
were analyzed by web-based software programs, David and Enricher. It was found that genes 
involved in drug metabolism as well as in bile acid synthesis and energy homeostasis were 
affected by MK-4 treatment in hPXR mice. Expression levels of these genes in MK-4-treated 
hPXR and WT mice as well as in Rif-treated hPXR mice are compared in Table 1. The ratios 
were deduced by comparisons with respective control groups. Furthermore, it was found that the 
effects of MK-4 on PXR target genes in hPXR mice were different from those of Rif in hPXR 
mice or MK-4 in WT mice. 
The data regarding some genes of interest obtained from DNA microarray was also 
evaluated by qRT PCR. From qRT PCR data it was found that though MK-4 treatment had no 
effect on the expression of typical PXR target genes in hPXR mice, MK-4 treatment significantly 
affected mRNA levels of ATP-binding cassette, sub-family A, member 3 (Abca3), cytochrome 
P450, family 2, subfamily s, polypeptide 1 (Cyp2s1), and sulfotransferase family 1B, member 1 
(Sult1b1) genes in liver (Figure 9B), which are not known as common targets of PXR. In contrast, 
WT mice were almost unaffected by MK-4 treatment (Figure 9C). 
In accordance with other studies, Rif had a tendency to suppress Cyp7a1 (cytochrome 
P450, family 7, subfamily a, polypeptide 1) which encodes rate limiting enzyme in bile synthesis, 
expression in hPXR mice though the effect did not reach statistical significance. mRNA level of 
Cyp8b1 (cytochrome P450, family 8, subfamily b, polypeptide 1) which encodes another 
important enzyme of bile acid synthesis, was not significantly altered by Rif treatment either 
(Figure 10A, upper). However, mRNA levels of these genes were significantly reduced by MK-4 
treatment in hPXR mice (Figure 10A, middle), whereas in WT mice, expression levels of these 
genes were not significantly altered (Figure 10A, lower). Furthermore, though none of the energy 
homeostasis genes was affected by Rif treatment, expression levels of Aldoc (aldolase C) and 
Slc2a5 (solute carrier family 2 member 5) were significantly suppressed by MK-4 treatment in 
hPXR mice (Figure 10B, upper and middle). Interestingly, MK-4 treatment increased mRNA 
91
level of Aldoc in WT mice. However, expression levels of other energy homeostasis genes were 
not affected in WT mice (Figure 10B, lower). 
Because the administered MK-4 dose (100 mg/kg BW) was relatively higher than usual 
pharmacological doses (45 mg/day for the treatment of osteoporosis) in human, the effects of 
lower doses of MK-4 (10 or 50 mg/kg BW) on the mRNA levels of bile acid synthesis and 
energy homeostasis genes was investigated by qRT-PCR. Expression levels of Cyp7a1 and 
Cyp8b1 were significantly suppressed also by the treatment with lower doses of MK-4 in hPXR 
mice, but not in WT mice (Figure 11A). Energy homeostasis gene Slc2a5 mRNA level was 
suppressed by MK-4 at lower doses in hPXR mice (Figure 11B). However, in WT mice, Pdk4 
was significantly affected by the treatment with the lowest dose of MK-4 (Figure 11B). 
Figure 12 shows hepatic Cyp7a1 protein levels after 6 h of the treatment by different 
doses of MK-4. Even though mRNA levels of Cyp7a1 were decreased by MK-4 treatment after 6 
h of the treatment, protein levels were not changed significantly. Possibly, it may take longer 
time for MK-4 to affect the protein levels. 
From the above data it can be concluded that single administration of MK-4 (10-100 
mg/kg BW) may affects genes expression involved in drug metabolism as well as in bile acid 
synthesis and energy homeostasis. Moreover, these effects of MK-4 on PXR target genes in 
hPXR mice were different from those of Rif in hPXR mice or MK-4 in WT mice. 
 
 
Chapter 4: Effects of chronic pharmacological dose of MK-4 treatment on the 
expression of genes involved in drug metabolism, bile synthesis and energy 
homeostasis in hPXR mice. 
To investigate whether the effect of MK-4 is also consistently observed when treated by 
chronic pharmacological dose of MK-4, another study was conducted by treating the hPXR mice 
for 30 days. Figure 13 shows MK-4 content in the liver of hPXR mice after chronic treatment of 
MK-4 (75 mg/kg diet). The effects of MK-4 treatment on the mRNA levels of genes involved in 
drug metabolism, bile acid synthesis and energy homeostasis in hPXR mice are shown in Figure 
14. Drug metabolizing genes - Abca3 and Gstp1 were significantly reduced by the chronic 
treatment (Figure 14A). None of the genes involved in bile synthesis genes (Figure 14B) and 
energy homeostasis genes (Figure 14C) was significantly affected by the chronic MK-4 
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treatment. However, no significant change was observed in Cyp7a1 protein level either (Figure 
15). 
From the above data, it can be concluded that though pharmacological dose of MK-4 can 
modulate a few genes expression involved in drug metabolism, this dose is likely to be not 
enough to affect the expression of genes involved in bile acid synthesis or energy homeostasis. 
 
 
Chapter 5: Effects of MK-4 treatment on the expression of genes involved in 
bile synthesis and drug metabolism in human hepatocellular carcinoma cells. 
Because CYP7A1 and CYP8B1 are very important genes involved in bile acid synthesis, 
the effect of MK-4 on the expression levels of these genes in human hepatocarcinoma HepG2 
cells was investigated. Here the effects of MK-4 treatment at different concentration for 24 h was 
shown on mRNA levels of genes encoding proteins involved in bile synthesis and drug 
metabolism in HepG2 cells. After 24 h of the treatment with 30 µM MK-4, the expression levels 
of both genes involved in bile acid synthesis were markedly suppressed (Figure 16A) even 
though mRNA levels of CYP3A4 and MDR1 were not changed (Figure 16B). This data 
demonstrate that MK-4 may inhibit bile acid synthesis in human. 
 
 
Chapter 6: Conclusions 
The present study focused on the investigation of the novel function of MK-4 in mice 
with humanized PXR. The data showed that though chronic pharmacological dose of MK-4 
treatment had no significant effects on the expression of the genes involved in drug metabolism, 
bile acid synthesis and energy homeostasis in hPXR mice, high dose of MK-4 may affects these 
genes expression significantly. Because MK-4 is used as a nutraceutical, the results suggest that 
there is a risk of undesired interactions between high dose of MK-4 and prescribed drugs. 
Therefore, awareness of this potential nutraceutical-drug interaction is critical. Furthermore, 
because MK-4 may inhibit bile acid synthesis, MK-4 should have a protective effect in 
cholestasis. To our knowledge, this is the first study showing the effect of MK-4 in hPXR mice. 
Further study should be conducted to clarify the mechanism of how MK-4 modulates the gene 
expression through regulation of PXR.  
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In conclusion the present study demonstrates- 
1. Single administration of MK-4 altered mRNA levels of genes involved in drug metabolism, 
bile acid synthesis, and energy homeostasis possibly through the interaction with hPXR. 
2. In WT mice, the effect of MK-4 on the expression of these genes was much weaker. These 
data indicate that MK-4 is likely a strong ligand of human PXR and a weak modulator of 
murine PXR in the regulation of metabolism-related genes. 
3. The effects of MK-4 on PXR target genes in hPXR mice were different from those of Rif in 
hPXR mice or MK-4 in WT mice. 
4. Similar mRNA changes of CYP7A1 and CYP8B1 were observed in human 
hepatocarcinoma HepG2 cells treated with MK-4. These results suggest that MK-4 may 
modulate bile acid synthesis in human. 
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Figure 1: PXR pathway 
(RXR: Retinoid X receptor 
PXRE: PXR responsive element) 
 
 
 
 
 
 
 
Figure 2: Hinge region & LBD of human PXR are knocked-in to mouse PXR, resulting in 
chimeric protein having murine N-terminal domain & DBD. 
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 Figure 3: Effect of F2 diet on basal expression of drug metabolizing genes in liver of WT and 
hPXR mice. mRNA levels of genes that encode drug metabolizing proteins were measured by 
quantitative RT-PCR. The relative mRNA levels were normalized to the amount of eukaryotic 
translation elongation factor 1α1 mRNA. Data are expressed as the mean ± SEM, n = 4. $P < 
0.01, *P < 0.05, compared to WT group. 
 
 
Figure 4: Effect of CRF-1 diet on basal expression of drug metabolizing genes in liver of  WT 
and hPXR mice. mRNA levels of genes that encode drug metabolizing proteins were measured 
by quantitative RT-PCR. The relative mRNA levels were normalized to the amount of eukaryotic 
translation elongation factor 1α1 mRNA. Data are expressed as the mean ± SEM, n =3-4. 
 
Figure 5: Menaquinone-4 concentration in the liver of WT male mice at different time interval 
after treatment of menaquinone-4. The data are expressed as the mean ± SEM, n = 3.  
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 Figure 6: Menaquinone-4 concentration in the liver of wild type and hPXR mice after treatment 
of menaquinone-4. The data are expressed as the mean ± SEM, n = 4-5. * P < 0.05, compared to 
wild type groups. 
 
 
 
 
Figure 7: Effect of menaquinone-4 (MK-4) treatment on mRNA levels of drug metabolizing 
genes in liver of WT (A) and hPXR mice (B). mRNA levels of genes that encode drug 
metabolizing proteins were measured by quantitative RT-PCR. Data are expressed as the mean ± 
SEM, n = 4. $P < 0.01, compared to control group.  
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Figure 8: Venn diagram of differentially expressed genes between rifampicin/menaquinone-4 
treated and control mice. 
(A) Up-regulated (more than twice), (B) down-regulated (less than 0.5 fold), and (C) overall
differentially expressed genes of rifampicin (Rif) or menaquinone-4 (MK-4) treatment in
comparison with control (Cont) in hPXR mice. Overall, there are 29 shared differentially
expressed genes between Rif and MK-4 treated groups (8 up-regulated and 21 down-regulated).
502 (135 up-regulated and 367 down-regulated) and 590 (299 up-regulated and 291 down-
regulated) differentially expressed genes were unique for Rif and MK-4 treated mice,
respectively. (D) Up-regulated (more than twice), (E) down-regulated (less than 0.5 fold), and
(F) overall differentially expressed genes of menaquinone-4 (MK-4) treatment in comparison
with control (Cont) in hPXR and wild type (WT) mice. Overall, there are 26 shared differentially
expressed genes between MK-4 treated hPXR and WT groups (9 up-regulated and 17 down-
regulated).  593 (298 up-regulated and 295 down-regulated) and 437 (257 up-regulated and 180
down-regulated) differentially expressed genes were unique for MK-4 treated hPXR and WT
mice, respectively.
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Table 1: Comparison of fold changes of gene expression (compared to corresponding control) in 
WT (treated by MK-4) and hPXR  (treated by MK-4 or Rifampicin) mice 
Function Gene symbol WT MK-4 hPXR MK-4 hPXR Rif 
Drug 
metabolism 
Cyp1a1 1.05 2.56 1.42 
Abca3 0.84 2.31 0.60 
Cyp2s1 1.41 2.06 1.00 
Gstp1 0.87 2.02 1.28 
Aldh1b1 0.60 0.48 0.66 
Sult1b1 1.18 0.29 0.85 
Cyp3a11 1.45 1.43 1.72 
Ces2a 1.01 1.30 2.23 
Abcb1a 0.97 0.92 1.66 
Bile 
homeostasis 
Cyp7a1  2.24  0.07  0.39  
Cyp8b1  1.11  0.45  0.99  
Cyp39a1  0.93  1.82  1.12  
Nceh1  0.97  1.83  1.91  
Energy 
homeostasis 
Aldoc  1.44  0.44  0.73  
Lipin1  1.03  2.00  0.75  
Pdk4  0.61  2.12  0.96  
Slc2a5  0.99  0.51  0.71  
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 Figure 9: Effects of menaquinone-4 and rifampicin on the expression of drug metabolizing 
genes in the liver of wild type and hPXR mice. The data are expressed as the mean ± SEM, n = 
4-5. $P < 0.01, *P < 0.05, compared to control groups.  
 
Figure 10: Effects of menaquinone-4 and rifampicin on mRNA levels of genes involved in bile 
acid synthesis and energy homeostasis in the liver of wild-type and hPXR mice. The data are 
expressed as the mean ± SEM, n = 4-5. $P < 0.01, * P < 0.05, compared to control group.  
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 Figure 11: Effects of lower doses of menaquinone-4 on the expression of genes involved in bile 
acid synthesis and energy homeostasis. Mean ± SEM, n=4. $P < 0.01, *P < 0.05, compared to 
control.  
 
Figure 12: Effects of different doses of menaquinone-4 on CYP7A1 protein levels in WT and 
hPXR mice. The data are expressed as the mean ± SEM.  
 
Figure 13: Menaquinone-4 concentration in the liver of hPXR mice after chronic dose treatment 
of menaquinone-4. The data are expressed as the mean ± SEM, n = 6.  
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 Figure 14: Effect of chronic dose of MK-4 on mRNA levels of genes encoding proteins 
involved in drug metabolism (A), bile synthesis (B) and energy homeostasis (C) in hPXR mice. 
The data are expressed as the mean ± SEM, n = 6. * P < 0.05, compared to control groups.  
 
Figure 15: Effect of chronic dose of MK-4 on CYP7A1 protein level in hPXR mice. The data 
are expressed as the mean ± SEM, n = 6.  
 
Figure 16: Effects of menaquinone-4 on the expression of genes encoding bile synthesis (A) and 
drug metabolism (B) in human hepatocarcinoma HepG2 cells. The data are expressed as the 
mean ± SEM, n=3. *P < 0.05, compared to control.  
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に関する研究) 
論 文 審 査 の 結 果 の 要 旨
ビタミン Kは、血液凝固因子、骨タンパク質の活性化に必須の因子である。近年になり、転写
因子 NFκBの活性化阻害、cAMP依存性タンパク質リン酸化酵素の活性化などの新しい機能が発
見され、がん細胞の増殖阻害、性ホルモン産生促進、インスリン分泌増強などの作用を示す。さ
らに、ビタミン K2のひとつであるメナキノン‐4（MK-4）が、核内受容体スーパーファミリー
の pregnane X 受容体（PXR）のリガンドとして働き、幾つかの遺伝子の発現を転写レベルで制
御することも示されている。多くの処方薬や食品に含まれる脂溶性物質が PXR に結合し、受容
体を活性化させることができるが、種により働くリガンドが異なる。このことは、げっ歯類など
のモデル動物を使用した食品由来の脂溶性物質の評価において、PXR を仲介した機能を正しく
評価できていない可能性を示唆している。この問題を克服する目的で、ヒト PXR 遺伝子をマウ
ス Pxr 遺伝子と入れ替えた、ヒト PXR 導入（hPXR）マウスが開発されている。本研究では、
hPXRマウスにMK-4を投与した場合の遺伝子発現に及ぼす影響を解析した。hPXRマウスに薬
理量の MK-4、およびヒト PXR の典型的なリガンドであるリファンピシン（抗結核薬）を経口
投与し、6 時間後の肝臓での PXR 標的遺伝子の mRNA 量を測定した。また、野生型マウスに
MK-4を投与し、同様に解析した。その結果、hPXRマウスへリファンピシン投与した場合、PXR
の典型的な標的遺伝子である、Cyp3a11、Ces2a、Mdr1 mRNAは有意に増加した。一方、MK-4
を投与した hPXR、野生型マウスでは、これらの遺伝子のmRNA量は変化しなかった。続いて、
肝臓における遺伝子発現を DNA マイクロアレイによって網羅的に解析を行ったところ、hPXR
マウスにおいて、MK-4投与により、薬物代謝関連の Abca3、Cyp2s1、Sultb1が変化していた。
また、胆汁酸合成に関わる Cyp7a1、Cyp8b1 mRNAも、MK-4投与によって低下した。これら
の変化は、野生型マウスでは見られなかった。さらに、ヒト由来肝がん細胞をMK-4で処理する
と、CYP7A1、CYP8B1 mRNA の有意な低下が観察された。これらの結果より、MK-4 はヒト
型 PXR を介して薬物代謝関連遺伝子や胆汁酸合成遺伝子の発現を調節することが示唆された。
以上の結果は、ヒト型 PXR を導入したマウスで初めて明らかにしたビタミン K2 の新しい作用
であり、貴重な知見である。よって、審査委員一同は、本論文が博士の学位に値する研究である
と判断した。
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